{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004015","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.622665+00:00","generated_at":"2026-06-04T07:00:04.668476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GlycoMimetics reports Q4/FY2023 cash $41.8M; Phase 3 uproleselan topline in Q2 2024","bullets":["Cash and equivalents $41.8M at Dec 31, 2023, down from $47.9M at Dec 31, 2022.","Phase 3 uproleselan topline results expected Q2 2024; NDA submission by end-2024 if positive.","Phase 1a GMI-1687 met primary and secondary endpoints; research agreement with ASH RC for SCD.","R&D expenses FY2023 $20.1M (down from $28.4M); G&A $19.2M (flat vs $19.1M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004015","json":"https://secwatch.observer/filing/0001558370-24-004015.json","markdown":"https://secwatch.observer/filing/0001558370-24-004015.md","text":"https://secwatch.observer/filing/0001558370-24-004015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/0001558370-24-004015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/glyc-20240327x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:00:04.668476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75b4f89aefc6e108aca415c1496074c232be7912","claim":"CRESCENT BIOPHARMA, INC. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/0001558370-24-004015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}